| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 1997: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1996: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Research Abstract |
1. Big ET-1 analogues with the inhibitory activity on endothelin-converting enzyme-1 (ECE-1). Two big endothelin-1(big ET-1) analogues with the inhibitory activity on ECE-1, [F^<21>]big ET-1(18-34) and [A^<31>]big ET-1(18-34), were found by various amino acid substitution of big ET-1. Kinetics analyses showed that [F^<21>]big ET-1(18-34) is a competitive inhibitor and [A^<31>]big ET-1 (18-34) is a non-competitive inhibitor, suggesting that ECE-1 recognizes the P1 position and the C-terminal portion in a different fashon.
2. Clarification of intracellular site for big ET-1-conversion. It is important for the drug design to know where in the cell the big ET-1 is converted, however, the intracellular site for the conversion of big ET-1 has been controversial. In the present study, using a chimera of ECE-1 and green fluorescent protein (GFP), visible signal in living cells, it was revealed that endogenous big ET-1 is converted intracellularly, not on the cell surface.
3. Analyses of the properties of ECE-1 by mutagenesis of ECE-1 cDNA.Mutagenesis of human cDNA revealed that glycosylation of the extracellular C-terminal domain of ECE-1 is essential to the enzymatic activity, and that the transmembrane domain plays an important role in the completion of normal glycosylation.
|
